Literature DB >> 1568283

Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya.

P W Kok1, J Leeuwenburg, P Tukei, A L van Wezel, J G Kapsenberg, G van Steenis, A Galazka, S E Robertson, D Robinson.   

Abstract

A study was carried out in a rural community in Kenya to compare the humoral and intestinal immunity provided by three doses of oral poliovirus vaccine (OPV) and two or three doses of enhanced-potency inactivated poliovirus vaccine (IPV). The immunization series was started at 8-12 weeks of age and the interval between doses was 2 months. In children with low levels of maternal antibodies (i.e., those most at risk), the first dose of either vaccine stimulated antibody response. Children with high levels of maternal antibodies responded to the first dose of OPV, but not to that of IPV. Subsequent doses led to increases in the mean antibody titres with both vaccines. After three doses of OPV, the proportion of children with antibody titres of greater than or equal to 1:8 was 92% for type 1 virus, 98% for type 2, and 90% for type 3. After two doses of IPV the proportion of children with antibody titres of greater than or equal to 1:8 was 94%, 88%, and 97% for type 1, type 2, and type 3, respectively; after three doses of IPV, 100% of children had antibodies greater than or equal to 1:8 for types 1 and 3, and 98% for type 2. Intestinal immunity was tested with a challenge dose of type 1 OPV, but the dose used was too small to detect a significant difference between the vaccines.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Age Factors; Antibodies--analysis; Biology; Child; Delivery Of Health Care; Demographic Factors; Developing Countries; Eastern Africa; English Speaking Africa; Evaluation; Examinations And Diagnoses; Health; Health Services; Immunity; Immunization; Immunologic Factors; Kenya; Laboratory Examinations And Diagnoses; Physiology; Population; Population Characteristics; Population Dynamics; Primary Health Care; Rural Population; Time Factors; Vaccines; Youth

Mesh:

Substances:

Year:  1992        PMID: 1568283      PMCID: PMC2393334     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  24 in total

1.  Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency.

Authors:  E A Simoes; B Padmini; M C Steinhoff; M Jadhav; T J John
Journal:  Am J Dis Child       Date:  1985-10

2.  Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule.

Authors:  T A Swartz; R Handsher; P Stoeckel; J Drucker; P Caudrelier; A L Van Wezel; H Cohen; D Salk; J Salk
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

3.  Sero-conversion of infants to three doses of oral poliomyelitis vaccine.

Authors:  S A Tswana; C Berejena
Journal:  Cent Afr J Med       Date:  1988-12

4.  Monovalent neonatal polio immunization--a strategy for the developing world.

Authors:  B D Schoub; S Johnson; J McAnerney; L Gilbertson; K I Klaassen; S G Reinach
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

Review 5.  Poliomyelitis vaccines. Success and controversy.

Authors:  F M LaForce
Journal:  Infect Dis Clin North Am       Date:  1990-03       Impact factor: 5.982

6.  Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children.

Authors:  R W Sutter; P A Patriarca; S Brogan; P G Malankar; M A Pallansch; O M Kew; A G Bass; S L Cochi; J P Alexander; D B Hall
Journal:  Lancet       Date:  1991-09-21       Impact factor: 79.321

7.  Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.

Authors:  A B Sabin
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

8.  Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.

Authors:  H Faden; J F Modlin; M L Thoms; A M McBean; M B Ferdon; P L Ogra
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

9.  Randomised trial of alternative formulations of oral poliovaccine in Brazil.

Authors:  P A Patriarca; F Laender; G Palmeira; M J Oliveira; J Lima Filho; M C Dantes; M T Cordeiro; J B Risi; W A Orenstein
Journal:  Lancet       Date:  1988-02-27       Impact factor: 79.321

10.  Poliomyelitis outbreak in Israel in 1988: a report with two commentaries.

Authors:  P E Slater; W A Orenstein; A Morag; A Avni; R Handsher; M S Green; C Costin; A Yarrow; S Rishpon; O Havkin
Journal:  Lancet       Date:  1990-05-19       Impact factor: 79.321

View more
  5 in total

Review 1.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

2.  The WHO Global Programme for Vaccines and Immunization Vaccine Trial Registry.

Authors:  S E Robertson; M V Mayans; S Horsfall; P F Wright; J Clemens; B Ivanoff; P H Lambert
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

3.  Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana.

Authors:  M Osei-Kwasi; E A Afari; K Mimura; I Obeng-Ansah; W K Ampofo; F K Nkrumah
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

4.  Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines.

Authors: 
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

Review 5.  Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis.

Authors:  Edward P K Parker; Beate Kampmann; Gagandeep Kang; Nicholas C Grassly
Journal:  J Infect Dis       Date:  2014-03-31       Impact factor: 5.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.